Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Authors

  • Habib Yaribeygi Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. E-mail: habib.yari@yahoo.com https://orcid.org/0000-0002-1706-6212
  • Mina Maleki Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-4723-3058
  • Tannaz Jamialahamdi Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0001-9521-3153
  • Seyed Adel Moallem Department of Pharmacology and Toxicology, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq; Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0003-4507-2932
  • Amirhossein Sahebkar Department of Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran. E-mail: amir_saheb2000@yahoo.com https://orcid.org/0000-0002-8656-1444

DOI:

https://doi.org/10.17179/excli2023-6022

Keywords:

diabetes mellitus, sodium-glucose cotransporter-2 inhibitors, liver, non-alcoholic fatty liver disorders, fibrosis, hepatocellular carcinoma, cirrhosis

Abstract

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.

Downloads

Published

2023-04-21

How to Cite

Yaribeygi, H., Maleki, M., Jamialahamdi, T., Moallem, S. A., & Sahebkar, A. (2023). Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI Journal, 22, 403–414. https://doi.org/10.17179/excli2023-6022

Issue

Vol. 22 (2023)

Section

Review articles

Categories

License

Copyright (c) 2023 Habib Yaribeygi, Mina Maleki, Tannaz Jamialahamdi, Seyed Adel Moallem, Amirhossein Sahebkar

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)

<< < 1 2